Covid-19 roundup: AstraZeneca may not file its vaccine in the US; Ivermectin fails to reduce hospitalizations in large trial
AstraZeneca’s top researcher Mene Pangalos signaled that the company may cut away from submitting its Covid-19 vaccine to the US FDA for approval, citing months of discussions with the regulator.
“We don’t need to push it in places we are not needed or wanted,” Pangalos told the Financial Times on Thursday. “If we don’t end up submitting it for a BLA [biologics license application], I don’t think it will have an impact around the world.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.